Successful creation of a company worth Rs 16,700 crore with the help of AI

Complete news at a glance

  • Matthew Gallagher founded an AI-assisted telehealth company named Medvi, whose valuation has reached approximately $1.8 billion (₹16,700 crore).
  • Most of Medvi’s functions are powered by AI, minimizing the need for human resources and reducing costs.
  • Kompany sells GLP-1 drugs, which are used to treat diabetes and obesity, and retails them for around $300.

A few years ago, it seemed an impossible feat that a single person could build a billion-dollar company with the help of AI alone. But Matthew Gallagher of Los Angeles, America made it true. He founded a telehealth company named Medvi, which has reached a valuation of approximately $1.8 billion (₹16,700 crore) today.

How did Medvi become?

Matthew started his journey in 2024 with a capital of just $20,000. He built the entire structure of his website, marketing, customer support and sales with the help of AI tools. ChatGPT, Claude and Grok were used to create the website, while Midjourney and Runway were used for the ads. ElevenLabs was used to communicate with customers. Matthew even developed the ability to handle multiple meetings simultaneously by having his voice and face cloned by AI.

AI Company Medvi: Company’s specialty

According to the New York Times report, the biggest feature of Medvi is that almost all functions are powered by AI. When customers contact the company, they are answered by an AI chatbot. The requirement of human resources is minimal, which reduces costs and increases the speed of work.

AI Company Medvi: The Secret of Real Earnings

Although Medvi is based on AI, its real earning comes through a special medicine. The company sells GLP-1 drugs, which are used to treat diabetes and obesity. These drugs typically cost over $1000 in the US, while Medvi offers them for around $300. This is the reason why millions of people are joining this company and its growth is increasing rapidly.



Have any thoughts?

Share your reaction or leave a quick response — we’d love to hear what you think!

Comments are closed.